Get started
KRUNG THAI BANK PUBLIC CO LTDKRUNG THAI BANK PUBLIC CO LTDKRUNG THAI BANK PUBLIC CO LTD

KRUNG THAI BANK PUBLIC CO LTD

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

NOVOB80 trade ideas

Novo completely oversold🐂 Trade Idea: Long - NOVO 🔥 Account Risk: 20.00% 📈 Recommended Product: Stock 🔍 Entry: +/- 750.00 🐿 DCA: No 😫 Stop-Loss: 675.00 🎯 Take-Profit #1: 1,000.00 (50%) 🎯 Trail Rest: Yes 🚨🚨🚨 Important: Don’t forget to always wait for strong confirmation once possible entry zone is reached. Trade ideas don’t work all the time no matter how good they look. Do not get a victim of FOMO, there is always another trade idea waiting. 🚨🚨🚨 If you like what you see don’t forget to leave a comment 💬 or smash that like ❤️ button! — Novo Nordisk is completely oversold (in fear of RFK) and so is the rest of the Pharma sector as well. Nevertheless, Novo is still printing money and trial results for a new product should come in end 24 or beginning 25 for the oral version of the weight loss drug. The fear over political decisions in the US should be used to buy the Pharma sector. For me, it is Novo and Regeneron. — Disclaimer & Disclosures pursuant to §34b WpHG The trades shown here related to stocks, cryptos, commodities, ETFs and funds are always subject to risks. All texts as well as the notes and information do not constitute investment advice or recommendations. They have been taken from publicly available sources to the best of our knowledge and belief. All information provided (all thoughts, forecasts, comments, hints, advice, stop loss, take profit, etc.) are for educational and private entertainment purposes only. Nevertheless, no liability can be assumed for the correctness in each individual case. Should visitors to this site adopt the content provided as their own or follow any advice given, they act on their own responsibility.
OMXCOP:NOVO_BLong
by LGNDRY-Capital
2
Novo Nordisk (NVO): Beautiful Reversal Pattern is emerging Novo Nordisk price has charted a famous and beautiful reversal pattern - Head & Shoulders. We have 3 peaks with the middle one the tallest also called Head. The Right Shoulder inclines down so the magnitude of the bearish move is strong. The dotted line between valleys of the Head is called a Neckline. The bearish target for this reversal is located at the distance of Head's height subtracted from the breakdown point on the Neckline. So, the target is at $89. This area aligns very well with the bottom of last October and the peak of last May.
NYSE:NVO
by aibek
6
Holy Cow, A lot of Big Option Purchases Coming In!First price target for January is $90 and it could happen soon. Be careful as spike downs tend to have a lower low formed prior to reversal, this would create bullish divergence on RSI, MACD and more which is another to double down. Options chain for calls expiring 1/10/2025 show the $90 strike has 1,522 calls bought on Friday at .87 per contract. Not huge, bot overall the bias on NVO is buy the dip. long term target of well over 100
NYSE:NVOLong
by LeapTrades
1
Buy Opportunity for NVONovo Nordisk A/S – Financial Summary and Outlook (2024): Sales Growth: Up 23% in Danish kroner (DKK 204.7 billion) and 24% at constant exchange rates (CER). Operating Profit: Increased by 21% (DKK 91.6 billion). Net Profit: Rose 18% to DKK 72.8 billion. Product Highlights: Wegovy (Obesity): Sales surged 48% in Q3 (DKK 17.3 billion). Ozempic (Diabetes): Slight sales dip but remains a key contributor. Challenges: CagriSema Trial: Missed expected weight-loss targets, leading to stock decline. Outlook: Adjusted sales growth forecast: 23%-27%; operating profit: 21%-27% (CER). Focus remains on high-demand products (Wegovy, Ozempic) and R&D for future growth.
NYSE:NVOLong
by datavanza
Can Market Turbulence Create Future Innovation?In a dramatic turn of events that sent shockwaves through the pharmaceutical industry, Novo Nordisk's recent setback with its experimental obesity drug CagriSema presents a fascinating case study in market resilience and scientific progress. The company's stock plummeted 24% after trial results showed a 22.7% weight reduction efficacy, falling short of the anticipated 25% target. Yet, beneath this apparent disappointment lies a deeper story of pharmaceutical innovation and market adaptation. The obesity treatment landscape stands at a pivotal crossroads, with the market experiencing exponential growth from its modest beginnings to a staggering $24 billion industry in 2023. Novo Nordisk's journey, alongside competitor Eli Lilly, exemplifies how setbacks often catalyze breakthrough innovations. The CagriSema trial, involving 3,400 participants, represents a clinical study and a testament to the industry's commitment to addressing global health challenges. Looking ahead, this moment of market recalibration might well be remembered as a turning point in the evolution of obesity treatment. With projections suggesting a potential $200 billion market by the early 2030s, the current turbulence could drive even greater innovation and competition. The fact that only 57% of trial participants reached the highest CagriSema dose points to untapped potential and future opportunities for optimization, suggesting that today's apparent setback might pave the way for tomorrow's breakthroughs.
NYSE:NVOShort
by UDIS_View
NOVO Down TrendTREND The red trend line from 2022 has been broken. It may be doing a pullback for confirmation. It continues its movement within the orange channel that started in 2024. It may be the 3rd of the 5-wave. The green trend line from 2021 is the first target before the purple main support. The purple support formed in 2023 is the strongest level. It is also Fibo 0.618. MA 20-day (Red), 50-day (Orange) is cutting down from the top. 100-day (Turquoise) has been working as support since November. 200-day (Blue) intersects with the weekly main support (Purple). SUMMARY It is in a downtrend in the weekly and a typical reversal pattern is not seen. It may continue its movement in the direction of the blue arrow.
OMXCOP:NOVO_BShort
by EmreSrn
1
NVO Ozempic - retraced from $148 to $102 - read the notes.here is a link to a riview NVO is Ozempic -Ozempic - retraced from $148 to $102 - and I bought the shares NVO, today Nov. 22, 2024 - Why? November 22, 2024 Treating the entire USA population affected with type 2 Diabetes would cost $119 Billion USD. - not treating the population will costs $338 Billion in GDP losses. The answer is stupidly yes? must deliver Ozempic to all that need it. IF I AM GOING TO ENDORSE SOMETHING THAT WORKS, IT WILL BE OZEMPIC. Period. No gimmicks, no images of ripped guys looking like wet chihuahuas, nothing like it—one injection in the belly once per week with a dosage pen, and you are done. After COVID, I became a whale, and now I have shed all those pounds gained from being cooped in for 2 years.Moderate exercise, once or twice per week, and Ozempic—that is it. The FUD about it that is being spread regarding weakness and intestinal paralysis is fake; none of it happened to me. I have nothing to gain by telling you this, except that I did buy the shares just now because they reached the Fib 61.8% retracement. I know this drug is effective and would be beneficial for many people who are morbidly obese in America because of food contamination, especially Crisco in most baking goods. So get healthy! Ozempic will boost your ability to make insulin by helping melt away internal fat surrounding your liver and pancreas, preventing it from contracting and expanding properly to make insulin. If you are diabetic type 2, if you lose weight to your BMI number, you will likely beat diabetes for good. Ozempic is a great biological technical innovation. We are past nature; if it were not for modern medicine, half of the world would be dead. Why Ozempic is a Must Technological Innovation That Starts to Save Diabetics Ozempic, containing the active ingredient semaglutide, represents a significant advancement in the management of type 2 diabetes. Its innovative mechanism not only helps control blood sugar levels but also addresses related health issues, making it a vital tool in diabetes care. Global Impact of Type 2 Diabetes Type 2 diabetes is a major health crisis worldwide. According to the International Diabetes Federation (IDF), approximately 537 million adults were living with diabetes in 2021, with this number expected to rise to 643 million by 2030. The disease is associated with severe complications, leading to significant mortality rates. In fact, diabetes and its complications account for an estimated 4.2 million deaths annually. Lowering BMI and Restoring Insulin Production Reducing body mass index (BMI) is crucial for improving the body's ability to regulate insulin production. Studies indicate that weight loss can enhance insulin sensitivity and restore proper pancreatic function. A lower BMI often correlates with better glycemic control, reducing the risk of diabetes-related complications. Research has shown that losing just5-10% of body weightcan lead to significant improvements in blood sugar levels and overall health. The Need for Ozempic in Diabetes Management While Ozempic has proven effective for many patients, there is still a substantial need for its widespread use to combat the growing epidemic of type 2 diabetes. Increased access to Ozempic could help millions manage their condition more effectively. The exact amount of Ozempic required to significantly curb the proliferation of type 2 diabetes is difficult to quantify, but expanding its availability and integrating it into treatment plans can make a substantial difference. Economic Cost of Diabetes The economic burden of diabetes on society is staggering. In the United States alone, the total estimated cost of diagnosed diabetes was$327 billion in 2017, which includes medical expenses and lost productivity. This figure continues to rise as more individuals are diagnosed with type 2 diabetes. The impact on GDP is profound, as healthcare costs associated with managing diabetes strain public health systems and reduce overall economic productivity. Conclusion Ozempic stands out as a revolutionary technological innovation that has the potential to save lives and improve the quality of life for those living with type 2 diabetes. By lowering BMI and enhancing insulin production, it addresses critical aspects of diabetes management. As we continue to face rising rates of this chronic condition, increasing access to effective treatments like Ozempic will be essential in mitigating its impact on individuals and society as a whole. Your purchase of the stock NVO helps allocate resources more efficiently for this frm to grow and expand its reach and benefit to society. So when people ask you to invest responsible, you reply I do, I invest in things that are needed. Recalculated Cost of Ozempic Treatment for Type 2 Diabetics in the USA If we lower the cost of Ozempic to $330 per month, we can recalculate the total annual cost for treating all type 2 diabetics in the USA. Estimating the Total Cost for All Type 2 Diabetics Assuming there are approximately 30 million individuals with type 2 diabetes in the United States, the total annual cost can be calculated as follows: Total Cost=Number of Patients×Annual Cost per Patient Total Cost=Number of Patients×Annual Cost per Patient Total Cost=30,000,000×(330×12) = 30,000,000×3,960=118,800,000,000 Total Cost=30,000,000×(330×12)=30,000,000×3,960 = 118,800,000,000 Thus, the total estimated cost of Ozempic treatment for all type 2 diabetics in the USA would be around $119 billion annually. Comparison with Economic Costs of Diabetes Previously, we noted that the total estimated cost of diagnosed diabetes in the United States was approximately $327 billion in 2017. This figure encompasses medical expenses and lost productivity related to diabetes. Conclusion: The Need for Continued Access to Ozempic With the recalculated potential cost of providing Ozempic treatment to all type 2 diabetics at about $119 billion, this is significantly lower than the overall economic burden of diabetes.Given this context, it is crucial for the U.S. government to ensure that this critical therapy remains accessible to the entire population. Maintaining access to effective treatments like Ozempic is essential not only for improving health outcomes for individuals with diabetes but also for alleviating the broader economic impact associated with managing this chronic condition. Until comprehensive public health strategies can effectively address underlying issues such as food pollution and obesity, ensuring ongoing availability of Ozempic and similar therapies will be vital in combating type 2 diabetes in America. You may also want to look into Crispr Therapeutics - this one is the next 500 Trillion company, it is like medicine pre-penicillin to now. Now we are going from antibiotic medicine to Gene Therapies tailored, new, effective, few collateral effects, and maybe even immortality. - and I bought the shares NVO, today Nov. 22, 2024 - Why?
NYSE:NVOLong
by imcnf5c4ff
NOVO has developed an H&S formationAs others have also mentioned on Trading View, NOVO has developed an H&S formation. The formation is to some extent supported by volume. Volume should be large when forming the left shoulder 1, as well as when forming the head 2, and when the price goes down at the right shoulder 4, but when forming the right shoulder the volume should be low 3. It is not. Since May, the volume balance has been negative, i.e. high volume at the price bottom and low volume at the price peak. At 794, there will be a significant break of 3%, especially if it is supported by high volume. There is no significant break yet. The object is heading towards 629. An H&S formation is a reversal formation. NOVO has been in a bullish trend, according to MA. However, the price is now below SMA 200. The price momentum indicators go from sell to buy within a month on Trading View. The price is well below a red cloud in Ichimocu. It is not possible to say now whether we will have a significant break down or whether the price will recover. The forecast will depend on this. Fundamentally, analysts are predominantly positive about the stock. Many companies would like to enter the obesity market, but there are far from good results in a phase 1 study to a finished drug, if it becomes a drug at all. Disclaimer: I have a relatively large position in the stock, which I bought when the shares plunged during the covid19 epidemic. I have sold 1/4 share when the price had tripled, so I am thinking of sitting still now even in the face of the technical picture - I am long. In the past, price has fluctuated between two pivot lines at times. Then I have swing traded NOVO. NB: Remember you must do your own research and assessment before buying and selling.
OMXCOP:NOVO_B
by scorpiris
1
Revising the head and shoulders pattern on NOVOSince my previous analysis on Novo Nordisk OMXCOP:NOVO_B , the price has nearly reached the original target of 700. However, I have made slight adjustments to the head and shoulders pattern, which has consequently led to a revised target at the value area low of the range from late 2023 at around 670. At this point, I would not consider this an ideal time to initiate a short position on OMXCOP:NOVO_B . Instead, it appears to be more of a profit-taking opportunity for those who entered short positions near the levels indicated in my earlier post.
OMXCOP:NOVO_BShort
by madsroland
Novo Nordisk Correction: Key Levels & Opportunities for InvestorNovo Nordisk, Europe’s largest publicly traded company, has experienced exceptional growth, especially in the diabetes and obesity treatment markets. Known globally for its expertise in insulin production, Novo Nordisk has also recently expanded into the obesity treatment market with products like Wegovy, which have seen rapid adoption and driven substantial revenue gains. Strong financials and a robust R&D pipeline make it a leading global player, well-positioned for future growth in metabolic health. From a technical analysis perspective, Novo Nordisk faced resistance at the significant psychological level of €1000, struggling to break above this for several months. Eventually, the stock began a correction phase. Yes, it happens with large market-cap stocks as well. Such pullbacks provide strategic buying opportunities, particularly at former resistance levels where the stock previously consolidated, which are now potentially acting as support. Examples like Apple, Microsoft, and Google in 2022 show similar patterns, where prior minor resistance points offer ideal entries during corrections. Currently, Novo Nordisk is approaching an initial support level around €725, which may present a first entry point for those looking to add it to their portfolios gradually. This level allows for a cautious position, leaving room for additional buys if prices dip further. Should the stock decline, the next support zone lies between €500-€600, marked by a significant psychological level (€500) and a 50% drop from the peak. Kind of an ideal scenario for adding to the position. This approach sets a flexible plan for entering Novo Nordisk with room for adjustments based on market movements. Regards, Vaido
OMXCOP:NOVO_BLong
by VaidoVeek
NVO from $115.75 to $135MODs have suggested that I provide more detail about the picks I make. Sorry. I'm not as verbose as y'all, and I don't like things to be complicated. My trading plan is very simple. I buy or sell at top & bottom of parallel channels. I confirm when price hits Fibonacci levels. Bonus if a TTM Squeeze in in play. I hold until target is reached or end of year, when I can book a loss. So... Here's why I'm picking this symbol to do the thing. Price at bottom of channels (period 100 52 39 & 26) Stochastic Momentum Index (SMI) at oversold level TTM Squeeze is off TTM Squeeze momentum is spiked down VBSM is turning spiked negative Impulse MACD is spiked to the downside In at $115.75 Target is $135 or channel top
NYSE:NVOLong
by chancethepug
1
NVO broke structureI did end up cutting my losses on my NVO trade, I was not quick enough to sell the relief rally. This chart confirms the breakdown of the stock finally after all this time. I zoomed out and drew an optimistic demand zone on the monthly chart. I expect some consolidation around the 200 EMA at this point which is generally what these high momentum charts like to do when they break down. This blue ema will likely collide with the demand zone at some point. If I were to continue trading this it would be to short, but these stocks are very hard to short since they are story stocks, the GLP story remains strong but is experiencing FUD. My short-term target is 105$ Medium term the demand zone box I do not expect high momentum for a while with the recent headwinds
NYSE:NVOShort
by Apollo_21mil
NOVO NORDISK: recovering from sicknessThe current market setup for Novo shows a clear consolidation within the larger trend structure, indicating key decision points ahead for traders. If the resistence breaks and stays over it the stock should have a good time. It could be that the price falls to DKK750-710 but should recover from this point on. Thank you for taking the time to read my analysis. I look forward to hearing your thoughts. Best regards, Mattner. no investment advice
OMXCOP:NOVO_BLong
by MattnerFuture